CA2068987A1 - Muscle stimulator with variable duty cycle - Google Patents
Muscle stimulator with variable duty cycleInfo
- Publication number
- CA2068987A1 CA2068987A1 CA002068987A CA2068987A CA2068987A1 CA 2068987 A1 CA2068987 A1 CA 2068987A1 CA 002068987 A CA002068987 A CA 002068987A CA 2068987 A CA2068987 A CA 2068987A CA 2068987 A1 CA2068987 A1 CA 2068987A1
- Authority
- CA
- Canada
- Prior art keywords
- skeletal muscle
- cardiac
- sensing
- duty cycle
- heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36042—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of grafted tissue, e.g. skeletal muscle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
- A61M60/10—Location thereof with respect to the patient's body
- A61M60/122—Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body
- A61M60/126—Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body implantable via, into, inside, in line, branching on, or around a blood vessel
- A61M60/148—Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body implantable via, into, inside, in line, branching on, or around a blood vessel in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
- A61M60/10—Location thereof with respect to the patient's body
- A61M60/122—Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body
- A61M60/126—Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body implantable via, into, inside, in line, branching on, or around a blood vessel
- A61M60/161—Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body implantable via, into, inside, in line, branching on, or around a blood vessel mechanically acting upon the outside of the patient's blood vessel structure, e.g. compressive structures placed around a vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
- A61M60/10—Location thereof with respect to the patient's body
- A61M60/122—Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body
- A61M60/165—Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body implantable in, on, or around the heart
- A61M60/191—Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body implantable in, on, or around the heart mechanically acting upon the outside of the patient's native heart, e.g. compressive structures placed around the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
- A61M60/20—Type thereof
- A61M60/289—Devices for mechanical circulatory actuation assisting the residual heart function by means mechanically acting upon the patient's native heart or blood vessel structure, e.g. direct cardiac compression [DCC] devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
- A61M60/50—Details relating to control
- A61M60/508—Electronic control means, e.g. for feedback regulation
- A61M60/515—Regulation using real-time patient data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
- A61M60/50—Details relating to control
- A61M60/508—Electronic control means, e.g. for feedback regulation
- A61M60/515—Regulation using real-time patient data
- A61M60/531—Regulation using real-time patient data using blood pressure data, e.g. from blood pressure sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
- A61M60/80—Constructional details other than related to driving
- A61M60/855—Constructional details other than related to driving of implantable pumps or pumping devices
- A61M60/871—Energy supply devices; Converters therefor
- A61M60/882—Devices powered by the patient, e.g. skeletal muscle powered devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
- A61M60/20—Type thereof
- A61M60/247—Positive displacement blood pumps
- A61M60/253—Positive displacement blood pumps including a displacement member directly acting on the blood
- A61M60/268—Positive displacement blood pumps including a displacement member directly acting on the blood the displacement member being flexible, e.g. membranes, diaphragms or bladders
- A61M60/274—Positive displacement blood pumps including a displacement member directly acting on the blood the displacement member being flexible, e.g. membranes, diaphragms or bladders the inlet and outlet being the same, e.g. para-aortic counter-pulsation blood pumps
Abstract
Apparatus and method of controlling a muscle stimulator by varying the duty cycle. The muscle stimulator is particularly adapted to a skeletal muscle powered cardiac assist system. An activity or other sensor (104) is used to determine the requirement for cardiac output. A second electrical sensor (34) is used to determine the cardiac rate. The outputs of these two sensors are employed to select a duty cycle for muscle stimulation of the skeletal muscle (22). The duty cycle is lowered for reasons of efficiency and safety during periods of very high or very low cardiac rate or body activity. The number of stimulation pulses within a burst is similarly increased when cardiac demand is high to ensure maximum contractile force of the skeletal muscle (22) during each stimulation burst.
Description
~ W O 91/08006 PC~r/~S90/07092 2 ~
Ml~SCL~3 E3TIMIJLATOR ~I~H VARIABLE DI~TY CYCI.E
. . ..
CROSS REFERENCES ~O CO-PENDING ~PPLICATIONS .
This application is related to Serial No.
, filed , entitled "Steroid ~; Eluting Intramuscular Lead" by the same assignee; Serial No.
, filed __ , entitled "Muscle Contraction Control by Intramuscular Pressure Monitoring" by the same assignee; Serial No. _ , filed , entitled "Muscle Work Output Monitor by Intramuscular Temperature Variation Measurement" by the same assignee; and Serial No. , filed , entitled "Muscle Fitness Detection by Colorimetry" by the same assignee.
: .
~AC~GROIJND OF T~IE IN~JENI'ION
1. Field of the Invention - The present in~ention relates generally to the field of muscle stimulation, and more particularly, relates to monitoring of cardiac assist systems which are powered by skeletal muscle.
2. Descri~tion of t~e Prior Art - Cardiac assist systems do not replace the human heart but merely supplement it. Many techniques have been proposed using a variety of mechanical power sources. Typically these require some form of , percutaneous energy transfer, because of the difficulty in storing sufficient energy subcutaneously. Such systems are cumbersome and inconvenient for the patient and are prone to lnfection along the percutaneous energy transfer path.
A technique hoiding a great a deal of promise is to power the cardiac assist system from a surgically modified skeletal muscle. The cardiac assist system is thus powered by normal ; biochemical processes. U.S. Patent No. 4,813,952 issued to ;: 35 KhalaSalla teaches a number of configurations of a skeletal muscle powered cardiac assist system. U.S. Patent No.
4,4~1,268 issued to Cox teaches a technique for conditioning skeletal muscle to be used in such a cardiac assist system.
' . " `' `
.~ .
....... .... " ,,; . ~, .. , , ..................... ~ , . . , , :
: . - .. :; . , , . : - : , ,., . . ,, - - :
. i . .. . . ~ . . . , .. -WO 91/08006 PCI/US~0/070~2 ~ . .
c~a ~ 2 Whereas the feasibility of a skeletal muscle powered cardiac assist system has been established in the literature and the clinic, a practical system must address concerns regarding efficiency and safety of operation. Of specific concern is the tying of the rate of stimulation of the skeletal muscle directly to the heart rate. This seems appropriate in some instances, but care must be exercised - because of the wide range of possible rates. For example, it may be quite inefficient to stimulate the skeletaL muscle at the cardiac rate when the patient is at rest and requires only modest cardiac output. Similarly, it may be inefficient and even dangerous to stimulate skeletal muscle contraction at very high rates. The nature of the skeletal muscle stimulation may also be changed to improve efficiency over the range of available rates and cardiac demands.
, 8tJMM2~RY OF T~IB INVENTION
The present invention employs two sensors to control the rate and nature of stimulation of a chronically implanted skeletal muscle powered cardiac assist system. One of the sensors is that which measures the electrical activity of the heart. This sensor would normally be present in any cardiac assist system for purposes of synchronization. It is also used in a demand pacing system to determine natural heart activity. In the present invention this sensor is used to , measure cardiac rate. The duty cvcle of the skeletal muscle stimulation varies with this measured rate. At very high l`l rates the duty cycle is lowered to improve hemodynamic : efficiency and add safety to the system. ;
.
The second sensor is used to determlne cardiac demand.
In the preferred embodiment this is accomplished using an activity sensor although other types of sensors may be used, such as blood oxygen level. During periods of low demand, such as when the patient is at rest and the patient's heart requires little assistance, the duty cycle is lowered to ' ,' ':
. ' ~8~87 .
.:
improve overall efficiency. As cardiac demand increases, the duty cycle is increased ensuring that the patient's heart obtains greater assistance at higher loads. Above a very hlgh rate, the duty cycle is again decreased to improve overall hemodynamic efficiency and as a safety measure.
The nature of the skeletal muscle stimulation is also changed with cardiac demand. At low demand levels, the number of pulses in a given burst and the amplitude are decreased to improve efficiency. As demand is increased, pulse count and lOamplitude are increased to increase the amount of cardiac assistance. Pulse count and amplitude are again decreased at arbitrarily high cardiac rates as a safety measure.
.. . . .
; BRIEF DESCRIPTION OF ~HE D~A~INGS
lSOther ob~ects of the present invention and many of the attendant advantages of the present invention will be readily appreciated as the same become better understood by reference to the following detailed description when considered in connection with the accompanying drawings, in which like ~ 20reference numerals designate like parts throughout the figures - thereof and wherein:
Fig. 1 is a first embodiment of the present invention wherein the skeletal muscle is wrapped about the myocardium. `
i Fig. 2 is an alternative embodiment of the present ~ 25invention wherein the skeletal muscle is wrapped about the i` descending aorta.
Fig. 3 is an alternative embodiment of the present invention wherein the skeletal muscle performs counter i pulsation of the descending aorta. -30Fig. 4 is a block diagram of the implantable pulse generator of the present invention.
Fig. 5 is a graphical representation of stimulation pulse amplitude as a function of cardiac demand.
Fig. 6 is a graphical representation of number of 35stimulation pulses per burst as a function of cardiac demand.
'~
`:~
. .
'' .
.... ..... . .. . ..
.
~J~
iA ~ 3 Fig. 7 is a graphical representation of duty cycle as a function of cardiac demand.
~ ig. 8 is a graphical representation of stimulation rate as a function of cardiac rate.
DETAILED DESCRIPTION OF T~E PRBFERRED EMBODIMENTS
The present invention employs a sensor to monitor cardiac electrical activity and cardiac demand in a skeletal muscle ~ powered cardiac assist system. The invention uses the output ; 10 of these sensors to vary a number of parameters of the skeletal muscle stimulation to improve efficiency ~nd safety.
The parameters to be varied are duty cycle, pulse a~plitude, and the number of pulses per burst. The basic cardiac assist system may be configured in a variety of ways as described in -U.S. Patent No. 4,813,952 issued to Khalafalla, herein i incorporated by reference. Several of these configurations are discussed herein by way of illustration and are not intended to limit the present invention.
FIG. 1 is an embodiment of the present invention wherein , 20 skeletal muscle 22 is wrapped about human heart 100. Skeletal 'l muscle 22 is conditioned as a "slow twitch" muscle as ' described by Cox in U.S. Patent No. 4,411,268, herein :
;' incorporated by reference. Implantable pulse generator 36 is coupled to pacing lead 34 to produce a demand pacemaker as taught by Cox. In addition, implantable pulse generator 36 stimulates skeletal muscle 22 to contract in synchrony with human heart 100. Assistance to~human heart 100 is provided by the simultaneous contraction of skeletal muscle 22 to increase systolic pressure in descending aorta 102 and elsewhere in the circulatory system.
According to the present invention, implantable pulse generator 36 employs activity sensor 104 in addition to the .!,1 cardiac activity sensed via pacing lead 34. These inputs are used by implantable pulse generator 36 to adjust the various parameters of the skeletal muscle stimulation regimen as ~ ` ' ,';~: .
: , : , .
explained below. The parameters to be adjusted are duty cycle, pulse count, and pulse amplitude.
FIG. 2 is an alternative embodiment of the present invention. In this embodiment skeletal muscle 22 is wrapped about artificial chamber 20 which is inserted in series with descending aorta 102. Unlike the embodiment of FIG. 1, implantable pulse generator 36 stimulates skeletal muscle 22 to contract following evacuation of human heart 100. This is accomplished by the insertion of a delay between a paced or : 10 sensed beat of human heart 100 and the stimulation of sXeletal muscle 22 as discussed below.
FIG. 3 is a further embodiment wherein artificial chamber 20 is coupled external to descending aorta 102. In this configuration sXeletal muscle 22 is stimulated to counter pulse human heart 100. This raises diastolic pressure, thereby increasing perfusion of human heart lO0. This is accomplished by the generation by implantable pulse generator ;l 36 of a sufficient delay between a sensed or paced contraction of human heart 100 and stimulation of skeletal muscle 22 to cause the desired counter pulsation.
Fig. ~ is a block diagram of implantable pulse generator ~! 36. It includes a pacing generator 154 which operates in the demand mode as is known in the art. Basically, the electrical activity oP the patient's heart is monitored via pacing lead 34. Whenever a naturally occurring contraction of the heart is found, sense amplifier 156 detects it and notifies pacing generator 154. I~ this naturally occurring contraction is sensed within the allotted time, the output of pacing generator 154 is inhibited. However, if pacing generator 154 determines that sufficient time has elapsed since the last contraction of the heart, it produces a pulse which is conveyed to the heart via pacing lead 34 to artificially ` stimulate the desired contraction.
;` The main purpose of stimulation generator 166 is to produce a burst of pulses to cause contraction of skeletal ''.' .''' ' :~ .
,,' ' :
~.,.~\
~ ~ .
~ WO91/08006 PCT/US90/07092 J, ,, 6 muscle 22 in the proper timing relation to the contraction of the patient's heart. To do so, or-gate 160 produces an output whenever sense amplifier 156 senses a naturally occurring contraction or pacing generator 154 supplies an artificial ' 5 pacing pulse. In either situation, timing logic 162 is started to generate the desired amount of delay. This delay is nearly zero for the embodiment of Fig. 1, because maximum assistance to the myocardium is provided when skeletal muscle ' 22 contracts at the same time as the heart.
The embodiment of Fig. 2 requires a much longer delay.
~,~ This period is on the order of one-half of the cardiac cycle (i.e. R-to-R interval). The embodiment of Fig. 3 requires yet a slightly longer delay, being somewhat greater than one-half , of the cardiac cycle,. This is necessary because this embodiment is intended to increase diastolic pressure in the aorta.
~he output of timing logic 162 is a pulse which is , synchronous with the naturally sensed or artificially 1 stimulated contraction of the patient's heart but delayed in time according to the specific embodiment as described above.
This pulse is supplied to duty cycle timing circuit 164. This circuit is simply a variable digital counter which produces an output corresponding to a variable number of pulses received from timing logic 162. The normal output of duty cycle timing circuit 164 is one pulse for each pulse received from timing logic 162. This corresponds to the one-for-one stimulation , mode of skeletal muscle 22. A lesser ratio of output pulses , to input pulses is determined by overall'cardiac rate and "` anticipated cardiac demand.
Overall cardiac rate is determined by integrator 158. It , is a circuit which receives inputs from both sense amplifier , 156 and pacing generator 154 much as with or-gate 160. In this way integrator is notified of both naturally occurring ' and artificially paced contractions of the patient's heart.
~, 35 Integrator 158 simply integrates these two signals to produce :,.
.:
' ~ ' : :' .
. , .
~.:. . . . : . ... .. : ,. .: .. . . . .. .. . .
: . . . . , . ,: , . . . . - . .. . . . . : . -7 ~ 9~
an average current heart rate. This signal is sent to duty cycle timer circuit 164 to adjust the variable rate counter in a manner which is described in more detail below.
The antlcipated cardiac demand may be determined in a number of ways known in the art of cardiac pacing. These include without limitation, measurement or venous blood oxygen level, measurement of blood ph, determination of respiratory rate, computation of minute volume, and measurement of stroke volume. The preferred mode of the present invention uses an activity sensor such as found in Medtronic Activitrax\pacemakers. Those of skill in the art will readily be able to substitute yet other sensors to determine anticipated cardiac demand.
In the preferred embodiment, an activity sensor 104 is mounted permanently to the housing of implantable pulse generator 36. This activity sensor is preferably a piezo electric crystal which converts mechanical energy received at the housing of implantable pulse generator 36 to electrical energy. It has been shown in the literature that activity sensing in this way is a very good means for anticipating cardiac demand. The output of activity sensor 104 is amplified and integrated by signal processing circuit 152.
The result is a signal indicative of anticipated cardiac demand which is transferred to duty cycle timing circuit 164.
The output of duty cycle timing circuit 164 is a pulse train which is a variable number o~ counts of the output of timing logic 162. The exact relationship is described in more detail below. Stimulation generator 166 receives the output of duty cyc~e timing circuit 164 and generates an output burst of energy corresponding to each of the output pulses of duty cycle timing circuit 164. The number of pulses in this burst is determined in part by the output of signal processor 152 ` such that additional pulses are added to the burst when the anticipated cardiac demand becomes high.
Conditioning generator 168 supplies conditioning pulses .
. .
... ..
.
.::
r~
~t~ J ~
': 8 as needed. The stimulation pulses of stimulation generator 166 are combined with the conditioning pulses of conditioning ;- generator 168 and supplied to skeletal muscle 22 by stimulation lead 32.
5~n lternative implementation of implantable pulse generator 36 is through the use of a microprocessor controlled general purpose implantable pulse generator such as Prometheus pulse generator manufactured by Medtronic, B.V. of the Netherlands. The primary advantage of such an implementation 10is the ease with which such a programmable device can change ~; modes of operation. This is particularly useful when doing clinic~l research. A description of the use of such a device may be found in the paper "Pulse Generator for Biomechanical Cardiac Assistance by Counter- Pulsation Technique", by 15Grandjean, et al., published in the "Record of the Conference on Skeletal ~uscle for Cardiac Assist and Repair, Banff Sept.
28-Oct. 2, 1988", published by Futura Editions (August 1989).
Fig. 5 is a graphical representation of a relationship between the pulse amplitude and the anticipated cardiac 20demand. In this case anticipated cardiac demand corresponds to the appropriate cardiac rate which is determined from the output of activity sensor 104. This is computed in the manner known in the art from U.S. Patent No. 4,579,402 issued to Anderson, et al. As can be seen, points 202 and 204 25correspond to verv low and low anticipated cardiac demand, respectively. These are on the order of less than 70 beats per minute. At these rates, stimulation generator 166 supplies output pulses of minimum amplitude. These pulses i must be greater than the stimulation threshold of skeletal 30muscle 22. ~owever, considerable energy is saved through using an amplitude which is only slightly greater than this threshold.
Points 206 and 208 correspond to average and high anticipated cardiac demand, respectively. These correspond to ,35rates in the range of 70 to 120 beats per minute although the .
`' . .
: ' .: .
' . 2~i8~7 exact values are patient dependent. At this demand level, the cardiac loading is sufficient to ~enefit from the additional amplitude and therefore additional assurance of capture.
Point 210 is above 120 pulses per minute for most patients.
Again notice that this is the anticipated cardiac demand and not the actual heart rate.
; Fig. 6 is a graphical representation of the number ofpulses in a given stimulation burst as a function of anticipated cardiac demand. The ranges along the a~scissa are as explained above for most patients. Average and high anticipated cardiac demand again require the greatest number of pulses per burst and therefore the highest energy demand.
The number of pulses per burst is decreased at very high anticipated demands because efficiency is impaired if the individual pulse occur too frequently.
Fig. 7 is a graphical representation of the synchronization ratio performed by the variable counter of duty cycle timing circuit 164. A one-to-one synchronization ratio is used for average anticipated cardiac demand. This provides the greatest chronic assistance to the myocardium with the least battery consumption by implantable pulse ~ generator 36. The synchronization ratio is greater for less ; than average anticipated cardiac demand because less assistance is actually required. The synchronization ratio increases as the anticipated cardiac demand increases to ensure the fatigue of skeletal muscle 22 is minim~ized.
Fig. 8 is a graphical representation of actual cardiac ' rates on the ordinate in relation to actual rates of ' stimulation of skeletal muscle 22 along the ordinate abscissa.
Shown is the change in duty cycle with actual rate. The duty cycle is one-for-one in the typical patient in the range of 50 ' to lO0 beats per minute. At point 272, the actual cardiac rate is 100 beats per minute and the rate of stimulation of skeletal muscle 22 is 100 beats per minute. Above that rate, , 35 skeletal muscle 22 is stimulated only once for every two ,~
.. . . ..
," .
, . . .
W091tO8Q06 PCT/US90/07092 cardiac cycles. At point 280 (140 beats per minute), the duty cycle becomes one stimulation of skeletal muscle 22 for every three cardiac cycles.
Having thus described the preferred embodiments of the present invention, those of skill in the art will be able to ' readily apply these teachings to other embodiments without deviating from the scope of the claims hereto attached.
: ...
.. ' '' ,, '," ~ . .~ .
.-, .
''', ' ' , .':
"'` , .. ~`''',.
: :.. -... . .
. ' ' . .
, . "''',: ' ~"
. ;`'' '~i,'' , .'~' ' ~ .
. .
':'.''' .
.'.i : .
.. . ... .. ~ .. " ~ .. . . . . . .
' . ' "' ' ' '' ; . ' : ~ . ' ' ' ': ` ' '. , . ' '' ':: . .
Ml~SCL~3 E3TIMIJLATOR ~I~H VARIABLE DI~TY CYCI.E
. . ..
CROSS REFERENCES ~O CO-PENDING ~PPLICATIONS .
This application is related to Serial No.
, filed , entitled "Steroid ~; Eluting Intramuscular Lead" by the same assignee; Serial No.
, filed __ , entitled "Muscle Contraction Control by Intramuscular Pressure Monitoring" by the same assignee; Serial No. _ , filed , entitled "Muscle Work Output Monitor by Intramuscular Temperature Variation Measurement" by the same assignee; and Serial No. , filed , entitled "Muscle Fitness Detection by Colorimetry" by the same assignee.
: .
~AC~GROIJND OF T~IE IN~JENI'ION
1. Field of the Invention - The present in~ention relates generally to the field of muscle stimulation, and more particularly, relates to monitoring of cardiac assist systems which are powered by skeletal muscle.
2. Descri~tion of t~e Prior Art - Cardiac assist systems do not replace the human heart but merely supplement it. Many techniques have been proposed using a variety of mechanical power sources. Typically these require some form of , percutaneous energy transfer, because of the difficulty in storing sufficient energy subcutaneously. Such systems are cumbersome and inconvenient for the patient and are prone to lnfection along the percutaneous energy transfer path.
A technique hoiding a great a deal of promise is to power the cardiac assist system from a surgically modified skeletal muscle. The cardiac assist system is thus powered by normal ; biochemical processes. U.S. Patent No. 4,813,952 issued to ;: 35 KhalaSalla teaches a number of configurations of a skeletal muscle powered cardiac assist system. U.S. Patent No.
4,4~1,268 issued to Cox teaches a technique for conditioning skeletal muscle to be used in such a cardiac assist system.
' . " `' `
.~ .
....... .... " ,,; . ~, .. , , ..................... ~ , . . , , :
: . - .. :; . , , . : - : , ,., . . ,, - - :
. i . .. . . ~ . . . , .. -WO 91/08006 PCI/US~0/070~2 ~ . .
c~a ~ 2 Whereas the feasibility of a skeletal muscle powered cardiac assist system has been established in the literature and the clinic, a practical system must address concerns regarding efficiency and safety of operation. Of specific concern is the tying of the rate of stimulation of the skeletal muscle directly to the heart rate. This seems appropriate in some instances, but care must be exercised - because of the wide range of possible rates. For example, it may be quite inefficient to stimulate the skeletaL muscle at the cardiac rate when the patient is at rest and requires only modest cardiac output. Similarly, it may be inefficient and even dangerous to stimulate skeletal muscle contraction at very high rates. The nature of the skeletal muscle stimulation may also be changed to improve efficiency over the range of available rates and cardiac demands.
, 8tJMM2~RY OF T~IB INVENTION
The present invention employs two sensors to control the rate and nature of stimulation of a chronically implanted skeletal muscle powered cardiac assist system. One of the sensors is that which measures the electrical activity of the heart. This sensor would normally be present in any cardiac assist system for purposes of synchronization. It is also used in a demand pacing system to determine natural heart activity. In the present invention this sensor is used to , measure cardiac rate. The duty cvcle of the skeletal muscle stimulation varies with this measured rate. At very high l`l rates the duty cycle is lowered to improve hemodynamic : efficiency and add safety to the system. ;
.
The second sensor is used to determlne cardiac demand.
In the preferred embodiment this is accomplished using an activity sensor although other types of sensors may be used, such as blood oxygen level. During periods of low demand, such as when the patient is at rest and the patient's heart requires little assistance, the duty cycle is lowered to ' ,' ':
. ' ~8~87 .
.:
improve overall efficiency. As cardiac demand increases, the duty cycle is increased ensuring that the patient's heart obtains greater assistance at higher loads. Above a very hlgh rate, the duty cycle is again decreased to improve overall hemodynamic efficiency and as a safety measure.
The nature of the skeletal muscle stimulation is also changed with cardiac demand. At low demand levels, the number of pulses in a given burst and the amplitude are decreased to improve efficiency. As demand is increased, pulse count and lOamplitude are increased to increase the amount of cardiac assistance. Pulse count and amplitude are again decreased at arbitrarily high cardiac rates as a safety measure.
.. . . .
; BRIEF DESCRIPTION OF ~HE D~A~INGS
lSOther ob~ects of the present invention and many of the attendant advantages of the present invention will be readily appreciated as the same become better understood by reference to the following detailed description when considered in connection with the accompanying drawings, in which like ~ 20reference numerals designate like parts throughout the figures - thereof and wherein:
Fig. 1 is a first embodiment of the present invention wherein the skeletal muscle is wrapped about the myocardium. `
i Fig. 2 is an alternative embodiment of the present ~ 25invention wherein the skeletal muscle is wrapped about the i` descending aorta.
Fig. 3 is an alternative embodiment of the present invention wherein the skeletal muscle performs counter i pulsation of the descending aorta. -30Fig. 4 is a block diagram of the implantable pulse generator of the present invention.
Fig. 5 is a graphical representation of stimulation pulse amplitude as a function of cardiac demand.
Fig. 6 is a graphical representation of number of 35stimulation pulses per burst as a function of cardiac demand.
'~
`:~
. .
'' .
.... ..... . .. . ..
.
~J~
iA ~ 3 Fig. 7 is a graphical representation of duty cycle as a function of cardiac demand.
~ ig. 8 is a graphical representation of stimulation rate as a function of cardiac rate.
DETAILED DESCRIPTION OF T~E PRBFERRED EMBODIMENTS
The present invention employs a sensor to monitor cardiac electrical activity and cardiac demand in a skeletal muscle ~ powered cardiac assist system. The invention uses the output ; 10 of these sensors to vary a number of parameters of the skeletal muscle stimulation to improve efficiency ~nd safety.
The parameters to be varied are duty cycle, pulse a~plitude, and the number of pulses per burst. The basic cardiac assist system may be configured in a variety of ways as described in -U.S. Patent No. 4,813,952 issued to Khalafalla, herein i incorporated by reference. Several of these configurations are discussed herein by way of illustration and are not intended to limit the present invention.
FIG. 1 is an embodiment of the present invention wherein , 20 skeletal muscle 22 is wrapped about human heart 100. Skeletal 'l muscle 22 is conditioned as a "slow twitch" muscle as ' described by Cox in U.S. Patent No. 4,411,268, herein :
;' incorporated by reference. Implantable pulse generator 36 is coupled to pacing lead 34 to produce a demand pacemaker as taught by Cox. In addition, implantable pulse generator 36 stimulates skeletal muscle 22 to contract in synchrony with human heart 100. Assistance to~human heart 100 is provided by the simultaneous contraction of skeletal muscle 22 to increase systolic pressure in descending aorta 102 and elsewhere in the circulatory system.
According to the present invention, implantable pulse generator 36 employs activity sensor 104 in addition to the .!,1 cardiac activity sensed via pacing lead 34. These inputs are used by implantable pulse generator 36 to adjust the various parameters of the skeletal muscle stimulation regimen as ~ ` ' ,';~: .
: , : , .
explained below. The parameters to be adjusted are duty cycle, pulse count, and pulse amplitude.
FIG. 2 is an alternative embodiment of the present invention. In this embodiment skeletal muscle 22 is wrapped about artificial chamber 20 which is inserted in series with descending aorta 102. Unlike the embodiment of FIG. 1, implantable pulse generator 36 stimulates skeletal muscle 22 to contract following evacuation of human heart 100. This is accomplished by the insertion of a delay between a paced or : 10 sensed beat of human heart 100 and the stimulation of sXeletal muscle 22 as discussed below.
FIG. 3 is a further embodiment wherein artificial chamber 20 is coupled external to descending aorta 102. In this configuration sXeletal muscle 22 is stimulated to counter pulse human heart 100. This raises diastolic pressure, thereby increasing perfusion of human heart lO0. This is accomplished by the generation by implantable pulse generator ;l 36 of a sufficient delay between a sensed or paced contraction of human heart 100 and stimulation of skeletal muscle 22 to cause the desired counter pulsation.
Fig. ~ is a block diagram of implantable pulse generator ~! 36. It includes a pacing generator 154 which operates in the demand mode as is known in the art. Basically, the electrical activity oP the patient's heart is monitored via pacing lead 34. Whenever a naturally occurring contraction of the heart is found, sense amplifier 156 detects it and notifies pacing generator 154. I~ this naturally occurring contraction is sensed within the allotted time, the output of pacing generator 154 is inhibited. However, if pacing generator 154 determines that sufficient time has elapsed since the last contraction of the heart, it produces a pulse which is conveyed to the heart via pacing lead 34 to artificially ` stimulate the desired contraction.
;` The main purpose of stimulation generator 166 is to produce a burst of pulses to cause contraction of skeletal ''.' .''' ' :~ .
,,' ' :
~.,.~\
~ ~ .
~ WO91/08006 PCT/US90/07092 J, ,, 6 muscle 22 in the proper timing relation to the contraction of the patient's heart. To do so, or-gate 160 produces an output whenever sense amplifier 156 senses a naturally occurring contraction or pacing generator 154 supplies an artificial ' 5 pacing pulse. In either situation, timing logic 162 is started to generate the desired amount of delay. This delay is nearly zero for the embodiment of Fig. 1, because maximum assistance to the myocardium is provided when skeletal muscle ' 22 contracts at the same time as the heart.
The embodiment of Fig. 2 requires a much longer delay.
~,~ This period is on the order of one-half of the cardiac cycle (i.e. R-to-R interval). The embodiment of Fig. 3 requires yet a slightly longer delay, being somewhat greater than one-half , of the cardiac cycle,. This is necessary because this embodiment is intended to increase diastolic pressure in the aorta.
~he output of timing logic 162 is a pulse which is , synchronous with the naturally sensed or artificially 1 stimulated contraction of the patient's heart but delayed in time according to the specific embodiment as described above.
This pulse is supplied to duty cycle timing circuit 164. This circuit is simply a variable digital counter which produces an output corresponding to a variable number of pulses received from timing logic 162. The normal output of duty cycle timing circuit 164 is one pulse for each pulse received from timing logic 162. This corresponds to the one-for-one stimulation , mode of skeletal muscle 22. A lesser ratio of output pulses , to input pulses is determined by overall'cardiac rate and "` anticipated cardiac demand.
Overall cardiac rate is determined by integrator 158. It , is a circuit which receives inputs from both sense amplifier , 156 and pacing generator 154 much as with or-gate 160. In this way integrator is notified of both naturally occurring ' and artificially paced contractions of the patient's heart.
~, 35 Integrator 158 simply integrates these two signals to produce :,.
.:
' ~ ' : :' .
. , .
~.:. . . . : . ... .. : ,. .: .. . . . .. .. . .
: . . . . , . ,: , . . . . - . .. . . . . : . -7 ~ 9~
an average current heart rate. This signal is sent to duty cycle timer circuit 164 to adjust the variable rate counter in a manner which is described in more detail below.
The antlcipated cardiac demand may be determined in a number of ways known in the art of cardiac pacing. These include without limitation, measurement or venous blood oxygen level, measurement of blood ph, determination of respiratory rate, computation of minute volume, and measurement of stroke volume. The preferred mode of the present invention uses an activity sensor such as found in Medtronic Activitrax\pacemakers. Those of skill in the art will readily be able to substitute yet other sensors to determine anticipated cardiac demand.
In the preferred embodiment, an activity sensor 104 is mounted permanently to the housing of implantable pulse generator 36. This activity sensor is preferably a piezo electric crystal which converts mechanical energy received at the housing of implantable pulse generator 36 to electrical energy. It has been shown in the literature that activity sensing in this way is a very good means for anticipating cardiac demand. The output of activity sensor 104 is amplified and integrated by signal processing circuit 152.
The result is a signal indicative of anticipated cardiac demand which is transferred to duty cycle timing circuit 164.
The output of duty cycle timing circuit 164 is a pulse train which is a variable number o~ counts of the output of timing logic 162. The exact relationship is described in more detail below. Stimulation generator 166 receives the output of duty cyc~e timing circuit 164 and generates an output burst of energy corresponding to each of the output pulses of duty cycle timing circuit 164. The number of pulses in this burst is determined in part by the output of signal processor 152 ` such that additional pulses are added to the burst when the anticipated cardiac demand becomes high.
Conditioning generator 168 supplies conditioning pulses .
. .
... ..
.
.::
r~
~t~ J ~
': 8 as needed. The stimulation pulses of stimulation generator 166 are combined with the conditioning pulses of conditioning ;- generator 168 and supplied to skeletal muscle 22 by stimulation lead 32.
5~n lternative implementation of implantable pulse generator 36 is through the use of a microprocessor controlled general purpose implantable pulse generator such as Prometheus pulse generator manufactured by Medtronic, B.V. of the Netherlands. The primary advantage of such an implementation 10is the ease with which such a programmable device can change ~; modes of operation. This is particularly useful when doing clinic~l research. A description of the use of such a device may be found in the paper "Pulse Generator for Biomechanical Cardiac Assistance by Counter- Pulsation Technique", by 15Grandjean, et al., published in the "Record of the Conference on Skeletal ~uscle for Cardiac Assist and Repair, Banff Sept.
28-Oct. 2, 1988", published by Futura Editions (August 1989).
Fig. 5 is a graphical representation of a relationship between the pulse amplitude and the anticipated cardiac 20demand. In this case anticipated cardiac demand corresponds to the appropriate cardiac rate which is determined from the output of activity sensor 104. This is computed in the manner known in the art from U.S. Patent No. 4,579,402 issued to Anderson, et al. As can be seen, points 202 and 204 25correspond to verv low and low anticipated cardiac demand, respectively. These are on the order of less than 70 beats per minute. At these rates, stimulation generator 166 supplies output pulses of minimum amplitude. These pulses i must be greater than the stimulation threshold of skeletal 30muscle 22. ~owever, considerable energy is saved through using an amplitude which is only slightly greater than this threshold.
Points 206 and 208 correspond to average and high anticipated cardiac demand, respectively. These correspond to ,35rates in the range of 70 to 120 beats per minute although the .
`' . .
: ' .: .
' . 2~i8~7 exact values are patient dependent. At this demand level, the cardiac loading is sufficient to ~enefit from the additional amplitude and therefore additional assurance of capture.
Point 210 is above 120 pulses per minute for most patients.
Again notice that this is the anticipated cardiac demand and not the actual heart rate.
; Fig. 6 is a graphical representation of the number ofpulses in a given stimulation burst as a function of anticipated cardiac demand. The ranges along the a~scissa are as explained above for most patients. Average and high anticipated cardiac demand again require the greatest number of pulses per burst and therefore the highest energy demand.
The number of pulses per burst is decreased at very high anticipated demands because efficiency is impaired if the individual pulse occur too frequently.
Fig. 7 is a graphical representation of the synchronization ratio performed by the variable counter of duty cycle timing circuit 164. A one-to-one synchronization ratio is used for average anticipated cardiac demand. This provides the greatest chronic assistance to the myocardium with the least battery consumption by implantable pulse ~ generator 36. The synchronization ratio is greater for less ; than average anticipated cardiac demand because less assistance is actually required. The synchronization ratio increases as the anticipated cardiac demand increases to ensure the fatigue of skeletal muscle 22 is minim~ized.
Fig. 8 is a graphical representation of actual cardiac ' rates on the ordinate in relation to actual rates of ' stimulation of skeletal muscle 22 along the ordinate abscissa.
Shown is the change in duty cycle with actual rate. The duty cycle is one-for-one in the typical patient in the range of 50 ' to lO0 beats per minute. At point 272, the actual cardiac rate is 100 beats per minute and the rate of stimulation of skeletal muscle 22 is 100 beats per minute. Above that rate, , 35 skeletal muscle 22 is stimulated only once for every two ,~
.. . . ..
," .
, . . .
W091tO8Q06 PCT/US90/07092 cardiac cycles. At point 280 (140 beats per minute), the duty cycle becomes one stimulation of skeletal muscle 22 for every three cardiac cycles.
Having thus described the preferred embodiments of the present invention, those of skill in the art will be able to ' readily apply these teachings to other embodiments without deviating from the scope of the claims hereto attached.
: ...
.. ' '' ,, '," ~ . .~ .
.-, .
''', ' ' , .':
"'` , .. ~`''',.
: :.. -... . .
. ' ' . .
, . "''',: ' ~"
. ;`'' '~i,'' , .'~' ' ~ .
. .
':'.''' .
.'.i : .
.. . ... .. ~ .. " ~ .. . . . . . .
' . ' "' ' ' '' ; . ' : ~ . ' ' ' ': ` ' '. , . ' '' ':: . .
Claims (11)
1. Apparatus comprising:
a. a surgically prepared skeletal muscle mechanically coupled to a heart such that contraction of said surgically prepared skeletal muscle assists said heart;
b. means responsively coupled to said heart and said surgically prepared skeletal muscle for stimulating said skeletal muscle to assist said heart; and c. means responsively coupled to said stimulating means for sensing anticipated cardiac demand.
a. a surgically prepared skeletal muscle mechanically coupled to a heart such that contraction of said surgically prepared skeletal muscle assists said heart;
b. means responsively coupled to said heart and said surgically prepared skeletal muscle for stimulating said skeletal muscle to assist said heart; and c. means responsively coupled to said stimulating means for sensing anticipated cardiac demand.
2. Apparatus according to claim 1 further comprising:
means responsively coupled to said stimulating means and said sensing means for varying at least one parameter of the output of said stimulating means.
means responsively coupled to said stimulating means and said sensing means for varying at least one parameter of the output of said stimulating means.
3. Apparatus according to claim 2 wherein said at least one parameter includes pulse amplitude.
4. Apparatus according to claim 2 wherein said at least one parameter includes duty cycle.
5. Apparatus according to claim 2 wherein said at least one parameter includes number of pulses per burst.
6. Apparatus according to claim 2 wherein said at least one parameter includes pulse width.
7. Apparatus according to claim 2 wherein said at least one parameter includes pulse interval.
8. A method of assisting cardiac activity comprising:
a. surgically preparing a skeletal muscle;
b. positioning said skeletal muscle such that contraction of said skeletal muscle assists cardiac activity;
c. sensing at least one body parameter;
d. determining anticipated cardiac demand from said body parameter; and e. stimulating said skeletal muscle to contract in accordance with said anticipated cardiac demand.
a. surgically preparing a skeletal muscle;
b. positioning said skeletal muscle such that contraction of said skeletal muscle assists cardiac activity;
c. sensing at least one body parameter;
d. determining anticipated cardiac demand from said body parameter; and e. stimulating said skeletal muscle to contract in accordance with said anticipated cardiac demand.
9. A method according to claim 8 wherein said sensing at least one body parameter includes sensing body activity.
10. A method according to claim 8 wherein said sensing at least one body parameter includes sensing blood oxygen.
11. A method according to claim 8 wherein said sensing at least one body parameter includes sensing blood pressure.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US446,794 | 1989-12-06 | ||
US07/446,794 US5069680A (en) | 1989-12-06 | 1989-12-06 | Muscle stimulator with variable duty cycle |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2068987A1 true CA2068987A1 (en) | 1991-06-07 |
Family
ID=23773854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002068987A Abandoned CA2068987A1 (en) | 1989-12-06 | 1990-12-04 | Muscle stimulator with variable duty cycle |
Country Status (7)
Country | Link |
---|---|
US (1) | US5069680A (en) |
EP (1) | EP0504323B1 (en) |
JP (1) | JPH05506372A (en) |
AU (1) | AU636706B2 (en) |
CA (1) | CA2068987A1 (en) |
DE (1) | DE69017044T2 (en) |
WO (1) | WO1991008006A1 (en) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0536858B1 (en) * | 1991-09-12 | 1996-07-24 | BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin | Stimulation system for a skeletal muscle |
US5344385A (en) * | 1991-09-30 | 1994-09-06 | Thoratec Laboratories Corporation | Step-down skeletal muscle energy conversion system |
DE69213657T2 (en) * | 1991-11-04 | 1997-01-23 | Cardiac Pacemakers Inc | Implantable device for monitoring and stimulating the heart for diagnosis and therapy |
US5251621A (en) * | 1991-12-18 | 1993-10-12 | Telectronics Pacing Systems, Inc. | Arrhythmia control pacer using skeletal muscle cardiac graft stimulation |
US5324323A (en) * | 1992-09-09 | 1994-06-28 | Telectronics Pacing Systems, Inc. | Multiple channel cardiosynchronous myoplasty apparatus |
US5328442A (en) * | 1992-11-20 | 1994-07-12 | Siemens Pacesetter, Inc. | System and method for stimulating a heart having undergone cardiac myoplasty using a single-chamber pacemaker |
US5496353A (en) * | 1993-09-23 | 1996-03-05 | Grandjean; Pierre A. | End-of-life indication system for implantable pulse generator |
US5658237A (en) * | 1995-08-17 | 1997-08-19 | Medtronic, Inc. | Cardiac assist device having improved muscle stimulation |
US5702427A (en) * | 1996-03-28 | 1997-12-30 | Medtronic, Inc. | Verification of capture using pressure waves transmitted through a pacing lead |
CA2220770C (en) * | 1996-03-28 | 2004-08-17 | Medtronic, Inc. | Detection of pressure waves transmitted through catheter/lead body |
US6775574B1 (en) | 1997-11-07 | 2004-08-10 | Medtronic, Inc. | Method and system for myocardial infarction repair |
US7031775B2 (en) * | 1997-11-07 | 2006-04-18 | Medtronic, Inc. | Method and system for myocardial infarction repair |
US6151525A (en) * | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
US5980571A (en) * | 1997-12-11 | 1999-11-09 | Colin Corporation | Substitute-heart control apparatus |
US6086527A (en) * | 1998-04-02 | 2000-07-11 | Scimed Life Systems, Inc. | System for treating congestive heart failure |
US6110100A (en) * | 1998-04-22 | 2000-08-29 | Scimed Life Systems, Inc. | System for stress relieving the heart muscle and for controlling heart function |
US7481803B2 (en) | 2000-11-28 | 2009-01-27 | Flowmedica, Inc. | Intra-aortic renal drug delivery catheter |
US7329236B2 (en) | 1999-01-11 | 2008-02-12 | Flowmedica, Inc. | Intra-aortic renal drug delivery catheter |
US6749598B1 (en) | 1999-01-11 | 2004-06-15 | Flowmedica, Inc. | Apparatus and methods for treating congestive heart disease |
US7780628B1 (en) | 1999-01-11 | 2010-08-24 | Angiodynamics, Inc. | Apparatus and methods for treating congestive heart disease |
US7122019B1 (en) | 2000-11-28 | 2006-10-17 | Flowmedica Inc. | Intra-aortic renal drug delivery catheter |
US6450942B1 (en) | 1999-08-20 | 2002-09-17 | Cardiorest International Ltd. | Method for reducing heart loads in mammals |
US6839594B2 (en) * | 2001-04-26 | 2005-01-04 | Biocontrol Medical Ltd | Actuation and control of limbs through motor nerve stimulation |
US6907295B2 (en) | 2001-08-31 | 2005-06-14 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
US6892098B2 (en) | 2001-04-26 | 2005-05-10 | Biocontrol Medical Ltd. | Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders |
US6697658B2 (en) | 2001-07-02 | 2004-02-24 | Masimo Corporation | Low power pulse oximeter |
US7974693B2 (en) | 2001-08-31 | 2011-07-05 | Bio Control Medical (B.C.M.) Ltd. | Techniques for applying, configuring, and coordinating nerve fiber stimulation |
US8571653B2 (en) | 2001-08-31 | 2013-10-29 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
US7778711B2 (en) | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Reduction of heart rate variability by parasympathetic stimulation |
US7734355B2 (en) | 2001-08-31 | 2010-06-08 | Bio Control Medical (B.C.M.) Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US7885709B2 (en) | 2001-08-31 | 2011-02-08 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation for treating disorders |
US7778703B2 (en) | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Selective nerve fiber stimulation for treating heart conditions |
US7904176B2 (en) | 2006-09-07 | 2011-03-08 | Bio Control Medical (B.C.M.) Ltd. | Techniques for reducing pain associated with nerve stimulation |
US7029433B2 (en) * | 2002-03-16 | 2006-04-18 | Chang Sheldon S | Device for cardiac restoration |
US7844346B2 (en) | 2002-05-23 | 2010-11-30 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
US7321793B2 (en) | 2003-06-13 | 2008-01-22 | Biocontrol Medical Ltd. | Vagal stimulation for atrial fibrillation therapy |
US8204591B2 (en) | 2002-05-23 | 2012-06-19 | Bio Control Medical (B.C.M.) Ltd. | Techniques for prevention of atrial fibrillation |
WO2004110550A2 (en) | 2003-06-13 | 2004-12-23 | Biocontrol Medical Ltd. | Vagal stimulation for anti-embolic therapy |
US7561922B2 (en) | 2004-12-22 | 2009-07-14 | Biocontrol Medical Ltd. | Construction of electrode assembly for nerve control |
AU2003300779A1 (en) | 2002-09-20 | 2004-05-04 | Flowmedica, Inc. | Catheter system for renal therapy |
US20050197624A1 (en) | 2004-03-04 | 2005-09-08 | Flowmedica, Inc. | Sheath for use in peripheral interventions |
US7063679B2 (en) | 2002-09-20 | 2006-06-20 | Flowmedica, Inc. | Intra-aortic renal delivery catheter |
JP2006508776A (en) | 2002-09-20 | 2006-03-16 | フローメディカ,インコーポレイテッド | Method and apparatus for selective substance delivery via an intrarenal catheter |
EP1585572A4 (en) | 2002-09-20 | 2010-02-24 | Flowmedica Inc | Method and apparatus for intra aortic substance delivery to a branch vessel |
US7585836B2 (en) | 2004-05-14 | 2009-09-08 | Goodson Iv Harry Burt | Bi-lateral local renal delivery for treating congestive heart failure and for BNP therapy |
US7993325B2 (en) | 2002-09-20 | 2011-08-09 | Angio Dynamics, Inc. | Renal infusion systems and methods |
US7627384B2 (en) * | 2004-11-15 | 2009-12-01 | Bio Control Medical (B.C.M.) Ltd. | Techniques for nerve stimulation |
US8880192B2 (en) | 2012-04-02 | 2014-11-04 | Bio Control Medical (B.C.M.) Ltd. | Electrode cuffs |
US8060197B2 (en) | 2003-05-23 | 2011-11-15 | Bio Control Medical (B.C.M.) Ltd. | Parasympathetic stimulation for termination of non-sinus atrial tachycardia |
EP1635736A2 (en) | 2003-06-05 | 2006-03-22 | FlowMedica, Inc. | Systems and methods for performing bi-lateral interventions or diagnosis in branched body lumens |
JP5175092B2 (en) | 2004-06-01 | 2013-04-03 | クワラタ トレーディング リミティド | In vitro technology using stem cells |
US7775966B2 (en) | 2005-02-24 | 2010-08-17 | Ethicon Endo-Surgery, Inc. | Non-invasive pressure measurement in a fluid adjustable restrictive device |
US8609082B2 (en) | 2005-01-25 | 2013-12-17 | Bio Control Medical Ltd. | Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesis |
US7658196B2 (en) | 2005-02-24 | 2010-02-09 | Ethicon Endo-Surgery, Inc. | System and method for determining implanted device orientation |
US7775215B2 (en) | 2005-02-24 | 2010-08-17 | Ethicon Endo-Surgery, Inc. | System and method for determining implanted device positioning and obtaining pressure data |
US7699770B2 (en) | 2005-02-24 | 2010-04-20 | Ethicon Endo-Surgery, Inc. | Device for non-invasive measurement of fluid pressure in an adjustable restriction device |
US7927270B2 (en) | 2005-02-24 | 2011-04-19 | Ethicon Endo-Surgery, Inc. | External mechanical pressure sensor for gastric band pressure measurements |
US8066629B2 (en) | 2005-02-24 | 2011-11-29 | Ethicon Endo-Surgery, Inc. | Apparatus for adjustment and sensing of gastric band pressure |
US8016744B2 (en) | 2005-02-24 | 2011-09-13 | Ethicon Endo-Surgery, Inc. | External pressure-based gastric band adjustment system and method |
ATE468808T1 (en) | 2005-03-01 | 2010-06-15 | Masimo Laboratories Inc | NON-INVASIVE MULTIPARAMETER PATIENT MONITOR |
TW200734462A (en) | 2006-03-08 | 2007-09-16 | In Motion Invest Ltd | Regulating stem cells |
US8152710B2 (en) | 2006-04-06 | 2012-04-10 | Ethicon Endo-Surgery, Inc. | Physiological parameter analysis for an implantable restriction device and a data logger |
US8870742B2 (en) | 2006-04-06 | 2014-10-28 | Ethicon Endo-Surgery, Inc. | GUI for an implantable restriction device and a data logger |
US7771401B2 (en) | 2006-06-08 | 2010-08-10 | Angiodynamics, Inc. | Selective renal cannulation and infusion systems and methods |
US20080027694A1 (en) * | 2006-07-12 | 2008-01-31 | Yury Michael Gitman | Heartbeat Simulation Method And Apparatus |
EP2125100B1 (en) | 2007-03-09 | 2021-08-25 | Mainstay Medical Limited | Muscle stimulator |
US11679262B2 (en) | 2007-03-09 | 2023-06-20 | Mainstay Medical Limited | Systems and methods for restoring muscle function to the lumbar spine |
US9072897B2 (en) | 2007-03-09 | 2015-07-07 | Mainstay Medical Limited | Systems and methods for restoring muscle function to the lumbar spine |
US11331488B2 (en) | 2007-03-09 | 2022-05-17 | Mainstay Medical Limited | Systems and methods for enhancing function of spine stabilization muscles associated with a spine surgery intervention |
US11679261B2 (en) | 2007-03-09 | 2023-06-20 | Mainstay Medical Limited | Systems and methods for enhancing function of spine stabilization muscles associated with a spine surgery intervention |
US10925637B2 (en) | 2010-03-11 | 2021-02-23 | Mainstay Medical Limited | Methods of implanting electrode leads for use with implantable neuromuscular electrical stimulator |
US8187163B2 (en) | 2007-12-10 | 2012-05-29 | Ethicon Endo-Surgery, Inc. | Methods for implanting a gastric restriction device |
US8100870B2 (en) | 2007-12-14 | 2012-01-24 | Ethicon Endo-Surgery, Inc. | Adjustable height gastric restriction devices and methods |
US8377079B2 (en) | 2007-12-27 | 2013-02-19 | Ethicon Endo-Surgery, Inc. | Constant force mechanisms for regulating restriction devices |
US8142452B2 (en) | 2007-12-27 | 2012-03-27 | Ethicon Endo-Surgery, Inc. | Controlling pressure in adjustable restriction devices |
US8192350B2 (en) | 2008-01-28 | 2012-06-05 | Ethicon Endo-Surgery, Inc. | Methods and devices for measuring impedance in a gastric restriction system |
US8591395B2 (en) | 2008-01-28 | 2013-11-26 | Ethicon Endo-Surgery, Inc. | Gastric restriction device data handling devices and methods |
US8337389B2 (en) | 2008-01-28 | 2012-12-25 | Ethicon Endo-Surgery, Inc. | Methods and devices for diagnosing performance of a gastric restriction system |
US8221439B2 (en) | 2008-02-07 | 2012-07-17 | Ethicon Endo-Surgery, Inc. | Powering implantable restriction systems using kinetic motion |
US7844342B2 (en) | 2008-02-07 | 2010-11-30 | Ethicon Endo-Surgery, Inc. | Powering implantable restriction systems using light |
US8114345B2 (en) | 2008-02-08 | 2012-02-14 | Ethicon Endo-Surgery, Inc. | System and method of sterilizing an implantable medical device |
US8591532B2 (en) | 2008-02-12 | 2013-11-26 | Ethicon Endo-Sugery, Inc. | Automatically adjusting band system |
US8057492B2 (en) | 2008-02-12 | 2011-11-15 | Ethicon Endo-Surgery, Inc. | Automatically adjusting band system with MEMS pump |
US8034065B2 (en) | 2008-02-26 | 2011-10-11 | Ethicon Endo-Surgery, Inc. | Controlling pressure in adjustable restriction devices |
US8187162B2 (en) | 2008-03-06 | 2012-05-29 | Ethicon Endo-Surgery, Inc. | Reorientation port |
US8233995B2 (en) | 2008-03-06 | 2012-07-31 | Ethicon Endo-Surgery, Inc. | System and method of aligning an implantable antenna |
EP2326239B1 (en) | 2008-07-03 | 2017-06-21 | Masimo Laboratories, Inc. | Protrusion for improving spectroscopic measurement of blood constituents |
US20100030040A1 (en) | 2008-08-04 | 2010-02-04 | Masimo Laboratories, Inc. | Multi-stream data collection system for noninvasive measurement of blood constituents |
US11684774B2 (en) | 2010-03-11 | 2023-06-27 | Mainstay Medical Limited | Electrical stimulator for treatment of back pain and methods of use |
US9999763B2 (en) | 2012-06-13 | 2018-06-19 | Mainstay Medical Limited | Apparatus and methods for anchoring electrode leads adjacent to nervous tissue |
WO2011112773A2 (en) | 2010-03-11 | 2011-09-15 | Mainstay Medical, Inc. | Modular stimulator for treatment of back pain, implantable rf ablation system and methods of use |
US11786725B2 (en) | 2012-06-13 | 2023-10-17 | Mainstay Medical Limited | Systems and methods for restoring muscle function to the lumbar spine and kits for implanting the same |
US9950159B2 (en) | 2013-10-23 | 2018-04-24 | Mainstay Medical Limited | Systems and methods for restoring muscle function to the lumbar spine and kits for implanting the same |
US8788045B2 (en) | 2010-06-08 | 2014-07-22 | Bluewind Medical Ltd. | Tibial nerve stimulation |
US9186504B2 (en) | 2010-11-15 | 2015-11-17 | Rainbow Medical Ltd | Sleep apnea treatment |
US9457186B2 (en) | 2010-11-15 | 2016-10-04 | Bluewind Medical Ltd. | Bilateral feedback |
US9108053B2 (en) | 2011-12-19 | 2015-08-18 | Mainstay Medical Limited | Apparatus and methods for rehabilitating a muscle and assessing progress of rehabilitation |
US20150018728A1 (en) | 2012-01-26 | 2015-01-15 | Bluewind Medical Ltd. | Wireless neurostimulators |
US9186501B2 (en) | 2012-06-13 | 2015-11-17 | Mainstay Medical Limited | Systems and methods for implanting electrode leads for use with implantable neuromuscular electrical stimulator |
US10195419B2 (en) | 2012-06-13 | 2019-02-05 | Mainstay Medical Limited | Electrode leads for use with implantable neuromuscular electrical stimulator |
WO2014087337A1 (en) | 2012-12-06 | 2014-06-12 | Bluewind Medical Ltd. | Delivery of implantable neurostimulators |
US9370660B2 (en) | 2013-03-29 | 2016-06-21 | Rainbow Medical Ltd. | Independently-controlled bidirectional nerve stimulation |
AU2014338621B2 (en) | 2013-10-23 | 2019-07-18 | Mainstay Medical Limited | Systems and methods for restoring muscle function to the lumbar spine |
US10471268B2 (en) | 2014-10-16 | 2019-11-12 | Mainstay Medical Limited | Systems and methods for monitoring muscle rehabilitation |
US9597521B2 (en) | 2015-01-21 | 2017-03-21 | Bluewind Medical Ltd. | Transmitting coils for neurostimulation |
US10004896B2 (en) | 2015-01-21 | 2018-06-26 | Bluewind Medical Ltd. | Anchors and implant devices |
US9764146B2 (en) | 2015-01-21 | 2017-09-19 | Bluewind Medical Ltd. | Extracorporeal implant controllers |
US9782589B2 (en) | 2015-06-10 | 2017-10-10 | Bluewind Medical Ltd. | Implantable electrostimulator for improving blood flow |
US10105540B2 (en) | 2015-11-09 | 2018-10-23 | Bluewind Medical Ltd. | Optimization of application of current |
US9713707B2 (en) | 2015-11-12 | 2017-07-25 | Bluewind Medical Ltd. | Inhibition of implant migration |
ES2874126T3 (en) | 2016-07-05 | 2021-11-04 | Mainstay Medical Ltd | Systems to restore muscle function in the lumbar spine and kits for its implantation |
US10327810B2 (en) | 2016-07-05 | 2019-06-25 | Mainstay Medical Limited | Systems and methods for enhanced implantation of electrode leads between tissue layers |
US10124178B2 (en) | 2016-11-23 | 2018-11-13 | Bluewind Medical Ltd. | Implant and delivery tool therefor |
US20180353764A1 (en) | 2017-06-13 | 2018-12-13 | Bluewind Medical Ltd. | Antenna configuration |
US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4143661A (en) * | 1977-12-12 | 1979-03-13 | Andros Incorporated | Power supply for body implant and method for operation |
US4140132A (en) * | 1978-03-23 | 1979-02-20 | Dahl Joseph D | Variable rate timer for a cardiac pacemaker |
US4457673A (en) * | 1980-11-28 | 1984-07-03 | Novacor Medical Corporation | Pump and actuator mechanism |
US4384829A (en) * | 1980-11-28 | 1983-05-24 | Andros Incorporated | Pump and actuator mechanism |
US4453537A (en) * | 1981-08-04 | 1984-06-12 | Spitzer Daniel E | Apparatus for powering a body implant device |
US4428378A (en) * | 1981-11-19 | 1984-01-31 | Medtronic, Inc. | Rate adaptive pacer |
US4411268A (en) * | 1982-02-10 | 1983-10-25 | Medtronic, Inc. | Muscle stimulator |
US4771765A (en) * | 1984-02-21 | 1988-09-20 | Choy Daniel S J | Heart assist device and method of use |
US4685446A (en) * | 1984-02-21 | 1987-08-11 | Choy Daniel S J | Method for using a ventricular assist device |
US4813952A (en) * | 1985-08-01 | 1989-03-21 | Medtronic, Inc. | Cardiac assist device |
US4666443A (en) * | 1986-04-18 | 1987-05-19 | Novacor Medical Corporation | Biventricular circulatory assist system and method |
US4759760A (en) * | 1986-10-30 | 1988-07-26 | Snapp Jr Edward A | Cardiovascular pump system |
-
1989
- 1989-12-06 US US07/446,794 patent/US5069680A/en not_active Expired - Fee Related
-
1990
- 1990-12-04 AU AU70794/91A patent/AU636706B2/en not_active Ceased
- 1990-12-04 WO PCT/US1990/007092 patent/WO1991008006A1/en active IP Right Grant
- 1990-12-04 JP JP91503227A patent/JPH05506372A/en not_active Withdrawn
- 1990-12-04 DE DE69017044T patent/DE69017044T2/en not_active Expired - Fee Related
- 1990-12-04 CA CA002068987A patent/CA2068987A1/en not_active Abandoned
- 1990-12-04 EP EP91902854A patent/EP0504323B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU636706B2 (en) | 1993-05-06 |
DE69017044T2 (en) | 1995-06-14 |
US5069680A (en) | 1991-12-03 |
WO1991008006A1 (en) | 1991-06-13 |
AU7079491A (en) | 1991-06-26 |
EP0504323A1 (en) | 1992-09-23 |
EP0504323B1 (en) | 1995-02-15 |
DE69017044D1 (en) | 1995-03-23 |
JPH05506372A (en) | 1993-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5069680A (en) | Muscle stimulator with variable duty cycle | |
US5358519A (en) | Muscle control and monitoring system | |
US5098442A (en) | Muscle contraction control by intramuscular pressure monitoring | |
US10124099B2 (en) | Physiologically responsive VAD | |
WO1993008874A1 (en) | Muscle control and monitoring system | |
US5807234A (en) | Myostimulator control using metabolic demand and muscle performance | |
US4856523A (en) | Rate-responsive pacemaker with automatic mode switching and/or variable hysteresis rate | |
US5089019A (en) | Muscle work output monitor by intramuscular temperature variation measurement | |
AU681907B2 (en) | End-of-life indication system for implantable pulse generator | |
US6406421B1 (en) | System and method of determining skeletal muscle contraction by serial lead impedance measurements | |
EP0443495A2 (en) | Hemodynamically rate-responsive pacemaker | |
WO2010019444A1 (en) | Pressure-driven intermittent pacing therapy | |
WO2010042535A2 (en) | Titrated intermittent pacing therapy | |
EP0634192B1 (en) | Heart stimulator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |